Spike Protein News and Research

RSS

Mechanistic insights into how the SARS-CoV-2 virus affects the nervous system, alters its function, and causes neuropathology

Study demonstrates that SARS-CoV-2 infection and viral fusogens cause glial and neuronal fusion.

9 Jun 2023

SARS-CoV-2 hijacks body's metabolism to amplify COVID-19 severity

In a review article published in the journal Signal Transduction and Targeted Therapy, scientists have discussed host metabolic alteration triggered by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and its effect on disease severity.

9 Jun 2023

Scientists unlock virus-fighting power with synthetic nanobody platform

Discovery and validation of nanobodies, a promising class of biologics, for viral infection prevention and treatment, including anti-SARS-CoV-2 nanobodies with enhanced neutralization properties through synergistic pairing. The study demonstrates the potential of nanobodies in developing effective therapies against viral infections.

8 Jun 2023

Single virus binds to a single receptor, study reveals

In Europe, the pandemic triggered in 2020 by the SARS-CoV-2 coronavirus is now largely under control. But why this virus is able to spread so efficiently remains unclear. A team of researchers led by Dr. Simone Backes, Dr. Gerti Beliu and Prof. Dr. Markus Sauer of the Julius Maximilians University of Würzburg (JMU) has now shown in a publication in "Angewandte Chemie" that some previous assumptions need to be reconsidered.

8 Jun 2023

A SARS-CoV-2 spike-targeting bispecific T-cell engager strategy for controlling SARS-CoV-2 infection

Researchers described a novel strategy for controlling severe acute respiratory syndrome coronavirus 2.

5 Jun 2023

Scientists investigate how immune system's T cells could fight many coronaviruses at once

Scientists at La Jolla Institute for Immunology (LJI) are investigating how the immune system's T cells react to a wide variety of coronaviruses, ranging from SARS to common cold coronaviruses.

1 Jun 2023

Experimental decoy provides long-term protection from SARS-Cov-2 infection

An experimental "decoy" provided long-term protection from infection by the pandemic virus in mice, a new study finds.

30 May 2023

Study maps immune responses produced by COVID-19 vaccination in First Nations population

Published in Nature Immunology and Nature Briefing, the research is the first of its kind to decisively map immune responses produced by a COVID-19 vaccination in any First Nations populations.

29 May 2023

MHRA authorizes new COVID-19 vaccine from SK Chemicals

SKYCovion, the COVID-19 vaccine developed by SK Chemicals, has today been authorized by the Medicines and Healthcare products Regulatory Agency (MHRA).

26 May 2023

Immune cells targeting core protein play an important role in early immune defense against COVID-19

LMU immunologists have studied the early immune response to acute SARS-CoV-2 infection and show how vaccines could be improved in future.

25 May 2023

New vaccine concept could lead to a new generation of vaccines against SARS-CoV-2

Researchers at the University of Basel have developed a new approach for a vaccine against COVID-19.

22 May 2023

Breast milk shields newborns: COVID-19 antibodies and microbiota from vaccinated mothers provide dual defense

Research paper discusses the differences in microbiota between high and low IgA subjects after the second dose of the COVID-19 vaccine. The study found that certain microbial features in breast milk can predict levels of anti-SARS-CoV-2 antibodies in breast milk one week post-second dose.

21 May 2023

Synthetic delivery vector STxB induces mucosal immunity against viral antigens

Research describes the development of a synthetic delivery vector called STxB for mucosal vaccination. It induces mucosal immunity, including resident memory CD8+ T cells and IgA antibodies, against antigens derived from mucosal viruses when administered intranasally in mice.

21 May 2023

A novel role for macrophage-activation signaling in orchestrating the recruitment process in response to the SARS-CoV-2 spike protein

Researchers derived peptides from the SARS-CoV-2 spike protein to assess COVID-19-associated inflammatory changes using zebrafish models.

19 May 2023

Cancer patients can initiate SARS-CoV-2 vaccination three months after bone marrow transplant

Patients with cancer whose immune systems are being supported or rebuilt by bone marrow transplantation should begin receiving vaccines for protection against SARS-CoV-2 three months post-transplant, according to a large, prospective, observational study led collaboratively by the Center for International Blood and Marrow Transplant Research, the Blood & Marrow Transplant Clinical Trials Network and Fred Hutchinson Cancer Center.

16 May 2023

SARS-CoV-2 variants show altered glycan processing

Researchers examine spike-protein trimers from SARS-CoV-2 variants to compare the N (asparagine)-glycan landscape.

15 May 2023

Deep generative models to generate hypothetical SARS-CoV-2 spike sequences

Scientists explore the use of deep generative models in producing complete instances of as-yet undiscovered SARS-CoV2 Spike protein sequences. The resulting models substantially outperform a state-of-the-art generative model for protein sequences finetuned on SARS-CoV2 data.

14 May 2023

Unlocking the secrets of Omicron: study reveals how unique spike mutations enable enhanced infectivity and resistance to immune barrier

Researchers reported the increased transmissibility of the severe acute respiratory syndrome coronavirus 2.

11 May 2023

Adenovirus and mRNA COVID vaccines differ in 6-month antibody durability

Research compares the durability of neutralizing antibody responses among recipients of three different COVID-19 vaccines (BNT162b2, mRNA-1273, and Ad26.COV2.S) over a period of 6 months.